{
    "organizations": [],
    "uuid": "bc22c87d102ab6bdb18f3ba7b6bd71122262ac46",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-clovis-oncology-receives-positive/brief-clovis-oncology-receives-positive-trend-vote-in-european-regulatory-review-ovarian-cancer-treatment-idUSASM000JKO",
    "ord_in_thread": 0,
    "title": "BRIEF-Clovis Oncology Receives Positive Trend Vote In European Regulatory Review Ovarian Cancer Treatment",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 21 (Reuters) - Clovis Oncology Inc:\n* CLOVIS ONCOLOGY RECEIVES POSITIVE TREND VOTE FROM CHMP IN EUROPEAN REGULATORY REVIEW FOR RUCAPARIB OVARIAN CANCER TREATMENT INDICATION\n* CLOVIS ONCOLOGY INC - PENDING A POSITIVE RECOMMENDATION BY CHMP FOR RUCAPARIB TABLETS, FINAL APPROVAL BY EUROPEAN COMMISSION WOULD FOLLOW IN Q2 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-22T06:20:00.000+02:00",
    "crawled": "2018-02-22T17:48:09.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "clovis",
        "oncology",
        "inc",
        "clovis",
        "oncology",
        "receives",
        "positive",
        "trend",
        "vote",
        "chmp",
        "european",
        "regulatory",
        "review",
        "rucaparib",
        "ovarian",
        "cancer",
        "treatment",
        "indication",
        "clovis",
        "oncology",
        "inc",
        "pending",
        "positive",
        "recommendation",
        "chmp",
        "rucaparib",
        "tablet",
        "final",
        "approval",
        "european",
        "commission",
        "would",
        "follow",
        "q2",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}